Wunderlich Securities Reiterates Abiomed Buy, $24 PT

Wunderlich Securities reiterated its Abiomed ABMD Buy rating and $24 price target in a research report published today. In the report, Wunderlich Securities states, "We expect several new catalysts for ABMD will emerge over the next few months, and we believe growth investors should aggressively take advantage of any pullback in ABMD shares." Shares of Abiomed were trading at $12.49, down 18.01% from Wednesday's market close.